3-氨基丙基(异丙基)氨基甲酸叔丁酯 | 1111236-12-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-氨基丙基(异丙基)氨基甲酸叔丁酯
• 英文名称: Tert-butyl 3-aminopropyl(isopropyl)carbamate
• 英文别名: tert-butyl N-(3-aminopropyl)-N-propan-2-ylcarbamate
• CAS: 1111236-12-4
• 化学式: C₁₁H₂₄N₂O₂
• mdl: MFCD11102239
• 分子量: 216.324
• InChiKey: FMJYSGLQUZZKNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  3-氨基丙基(异丙基)氨基甲酸叔丁酯 、 4-[5-(2,3-Dichlorophenyl)-2-methylpyrazol-3-yl]piperidine-1-sulfonyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Identification of nonpeptidic small-molecule inhibitors of interleukin-2

  摘要：

  The identification, design, and synthesis of a series of novel sulfamide- and urea-based small-molecule antagonists of the protein-protein interaction IL-2/IL-2Ralpha are described. Installation of a furan carboxylic acid fragment onto a low-micromolar sulfamide resulted in a 23-fold improvement in activity, providing a sub-micromolar, nonpeptidic IL-2 inhibitor (IC50 = 0.60 muM). (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.045
• 作为产物：
  描述：

  tert-butyl N-[3-(dibenzylamino)propyl]-N-propan-2-ylcarbamate 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 以94.3%的产率得到3-氨基丙基(异丙基)氨基甲酸叔丁酯
  参考文献：
  名称：

  [EN] PYRROLOPYRIMIDINES
  [FR] PYRROLOPYRIMIDINES

  摘要：

  本发明涉及化合物或其药用盐，制备它们的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及一类极化样激酶（PLKs）抑制剂化合物，用于治疗由PLK介导的疾病状态，特别是PLK4，特别是在治疗涉及异常细胞增殖的病理过程中有用的化合物，如肿瘤生长、类风湿性关节炎、再狭窄和动脉粥样硬化。

  公开号：

  WO2009016132A1

文献信息

• Diversion-resistant opioid formulations
  申请人：Elysium Therapeutics, Inc.

  公开号：US10314839B2

  公开（公告）日：2019-06-11

  The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors. The covalent bond between the polymer and the antagonist in the conjugate is broken over a defined period of time to release the antagonist into the formulation. The released antagonist attenuates the liking of the agonist, thereby eliminating the incentive to the diversion of the medicines.

  本发明提供了一种由阿片激动剂和聚合物-拮抗剂共轭物组成的组合物。聚合物-拮抗剂共轭物在给患者用药时最好不会水解，也不会与阿片受体结合。聚合物与拮抗剂共轭物之间的共价键会在一定时间内断裂，从而将拮抗剂释放到制剂中。释放出的拮抗剂会减弱激动剂的药效，从而消除药物转移的诱因。
• PYRROLOPYRIMIDINES
  申请人：Diels Gaston Stanislas Marcella

  公开号：US20100204197A1

  公开（公告）日：2010-08-12

  The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.
• DIVERSION-RESISTANT OPIOID FORMULATIONS
  申请人：Elysium Therapeutics, Inc.

  公开号：US20160136153A1

  公开（公告）日：2016-05-19

  The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors. The covalent bond between the polymer and the antagonist in the conjugate is broken over a defined period of time to release the antagonist into the formulation. The released antagonist attenuates the liking of the agonist, thereby eliminating the incentive to the diversion of the medicines.
• US8318731B2
  申请人：——

  公开号：US8318731B2

  公开（公告）日：2012-11-27
• [EN] PYRROLOPYRIMIDINES<br/>[FR] PYRROLOPYRIMIDINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009016132A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.

  本发明涉及化合物或其药用盐，制备它们的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及一类极化样激酶（PLKs）抑制剂化合物，用于治疗由PLK介导的疾病状态，特别是PLK4，特别是在治疗涉及异常细胞增殖的病理过程中有用的化合物，如肿瘤生长、类风湿性关节炎、再狭窄和动脉粥样硬化。